Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1
(NASDAQ:EVAX), Evaxion's AI-Immunology(TM) platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program combining these novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens Evaxion's proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen demonstrates superior performance compared to the traditional gB antigen, including […]